LIN vs REGN · P/E 34, rev $33.99B vs P/E 14, rev $14.34B
Linde plc Ordinary Shares (LIN) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the LIN and REGN stock pages for the full models.
Not investment advice.